BRCA1 is also rendered inactive in some cancers via BRCA1 promoter hypermethylation; it is likely that loss of BRCA1 methylation during or before treatment can also result in an effective reversion of the HR phenotype [8, 30, 31, 32]. Here, BRCA1 is linked to cancer.